Catawba River Capital’s Regeneron Pharmaceuticals Position
Does Catawba River Capital own Regeneron Pharmaceuticals (REGN)? Yes — 16.8K shares worth $13M (+6.27% of its 13F portfolio) as of Q1 2026, down from 29.3K shares the prior filed quarter.
Position Value
$13M
Q1 2026
Shares
16.8K
% of Portfolio
+6.27%
Quarters Held
19
currently held
Position History REGN
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 16.8K | $13M | +6.27% |
| Q4 2025 | 29.3K | $23M | +10.08% |
| Q3 2025 | 29.7K | $17M | +7.59% |
| Q2 2025 | 29.7K | $16M | +7.92% |
| Q1 2025 | 9.7K | $6M | +3.73% |
| Q4 2024 | 9.3K | $7M | +3.94% |
| Q3 2024 | 8.9K | $9M | +5.91% |
| Q2 2024 | 8.9K | $9M | +5.64% |
| Q1 2024 | 16.1K | $15M | +9.00% |
| Q4 2023 | 16.2K | $14M | +9.99% |
| Q3 2023 | 16.0K | $11M | +9.15% |
| Q2 2023 | 16.0K | $11M | +9.15% |
| Q1 2023 | 9.3K | $8M | +6.91% |
| Q4 2022 | 9.3K | $7M | +7.00% |
| Q3 2022 | 9.3K | $6M | +7.60% |
| Q2 2022 | 9.2K | $5M | +7.13% |
| Q1 2022 | 9.0K | $6M | +4.15% |
| Q4 2021 | 9.0K | $6M | +3.43% |
| Q3 2021 | 8.8K | $5M | +3.34% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Catawba River Capital’s full portfolio or all institutional holders of REGN.